Future of weight loss

More than 40% of Americans are now classified as obese while 75% of adults are either overweight or obese. A new group of drugs called GLP-1 receptor agonists have come on the scene to help in the battle to lose weight. Are they as good as we think?

You may have heard about them or some of their brand names like Zepbound, Wegovy, and Ozempic. The use of these drugs has exploded in popularity to the point where companies like Lilly and Novo Nordisk have had problems keeping up with demand. There is nothing magical about the science behind these drugs. GLP-1 mimics a protein naturally produced by our small intestines. The receptors for these medicines are located across the body. They help us lose weight because receptors in the gastrointestinal tract slow down and send signals to the brain that give us a sense of feeling full.

There are some side effects but nothing too serious for most patients. We are still learning how these medications impact the body. They are currently approved for treating diabetes, obesity, and those with a history of cardiovascular disease in people who are overweight. There are a few drawbacks to these drugs at present.

Typically, GLP-1 agonists are administered as injections in the abdomen, upper arms, outer thighs, or upper buttocks via a syringe and needle or a pre-filled dosing pen. The shots are generally taken once a day or once a week.

For many, this is a big turn-off. Fortunately, you will be able to take tablets soon. The typical weight loss is from 5-15% of body weight over at least 12 months. But GLP-1 is no quick fix. Like exercise, you must stick with it. If you stop taking it, most people regain the weight they lost. And you can’t expect to magically lose weight while you continue to eat all that junk food you get.

The second drawback is the expense. These medications’ list price is around $1,000 a month to $1,400 a month. Without insurance, we are talking $12,000 plus per year for these drugs. Many insurance plans cover some portion of GLP-1 costs, but the extent of coverage can vary significantly. You probably are wondering whether Medicare covers GLP-1 medications. They do for certain medically accepted indications such as heart attack or cardiovascular disease but not for weight management. To qualify, you must have a BMI of 30 or higher, or 27 or higher with comorbidities like high blood pressure, high cholesterol, or type 2 diabetes. They are currently covered through Part D plans.

An entirely new team of individuals, including a retired congressman, a surgeon, and a talk-show host could play pivotal roles in how the government goes about safeguarding America’s health.

Coinsurance amounts are pegged to the list price of drugs. As such, Medicare beneficiaries who qualify could still face monthly costs of $250 to $430 before they reach the annual out-of-pocket drug spending established by the Inflation Reduction Act (IRA). The IRA cap for out-of-pocket expenses were around $3,300 in 2024 and will be $2,000 in 2025. Most retirees living on modest incomes would still find the cost of GLP-1 prohibitive.

In November 2024, the Biden Administration proposed that Medicare and Medicaid cover obesity medications. In doing so, they sidestepped a twenty-year-old piece of legislation that prevented Medicare from covering drugs for ‘weight loss.’ The new proposal specifies that the drugs would be covered to treat the disease of obesity and prevent related conditions. Those conditions are serious and include diabetes, high blood pressure, cardiovascular disease, sleep apnea, fatty liver disease, and arthritis.

The classification would also mean that every state Medicaid program would be required to cover the drugs starting in 2026. Between the two programs, an additional 7.4 million Americans would gain coverage. The price tag would be high, at least $36 billion over a decade. However, there are more obesity drugs in the pipeline and prices should fall as competition heats up. Starting in 2025, Medicare will also be able to negotiate a lower price for Wegovy as well as many other popular drugs.

As for the future, the costs and usage of GLP-1 medications could change significantly under the second Trump Administration. An entirely new team of individuals, including a retired congressman, a surgeon, and a talk-show host could play pivotal roles in how the government goes about safeguarding America’s health.

Under Robert F. Kennedy, an environmental lawyer, politician, and anti-vaccine organizer, we can expect radically different views and actions in health care, medicine, food safety, and science research. Early indications are that Kennedy, who would run the Department of Health and Human Services, is not a big fan of Ozempic. He does not believe that using popular GLP-1 drugs is ever going to make America healthy again. His remedy would be to provide good food to Americans. He believes that providing three nutritious meals a day to all Americans would solve obesity and diabetes overnight. The problem is that for many Americans the admonition to change your diet, eat less, and exercise more has failed to dent the problem. Why not give the country an avenue that shows a much better chance of success over the long term?



Bill Schmick is a founding partner of Onota Partners, Inc., in the Berkshires.

The views expressed here are not necessarily those of The Millerton News and The News does not support or oppose candidates for public office.

Latest News

Out of the mouths of Ukrainian babes

To escape the cruelties of war, Katya finds solace in her imagination in “Sunflower Field”.

Krista A. Briggs

‘I can sum up the last year in three words: fear, love, hope,” said Oleksandr Hranyk, a Ukrainian school director in Kharkiv, in a February 2023 interview with the Associated Press. Fast forward to 2025, and not much has changed in his homeland. Even young children in Ukraine are echoing these same sentiments, as illustrated in two short films screened at The Moviehouse in Millerton on April 5, “Once Upon a Time in Ukraine” and “Sunflower Field.”

“Sunflower Field,” an animated short from Ukrainian filmmaker Polina Buchak, begins with a young girl, Katya, who embroiders as her world becomes unstitched with the progression of the war. To cope, Katya retreats into a vivid fantasy world, shielding herself from the brutal realities surrounding her life, all while desperately wanting her family to remain intact as she awaits a phone call from her father, one that may never come.

Keep ReadingShow less
William F. Buckley Jr.: a legacy rooted in Sharon
Provided

Sam Tanenhaus, when speaking about William F. Buckley, Jr., said he was drawn to the man by the size of his personality, generosity and great temperament. That observation was among the reasons that led Tanenhaus to spend nearly 20 years working on his book, “Buckley: The Life and Revolution That Changed America,” which is due out in June. Buckley and his family had deep roots in Sharon, living in the house called Great Elm on South Main Street, which was built in 1812 and bought by Buckley’s father in 1923.

The author will give a talk on “The Buckleys of Sharon” at the Sharon Historical Society on Saturday, April 12, at 11 a.m. following the group’s annual meeting. The book has details on the family’s life in Sharon, which will, no doubt, be of interest to local residents.

Keep ReadingShow less
Janet Marlow’s pet sounds

Janet Marlow recording Pet Acoustics.

Alan Brennan

Does your pet suffer from anxiety and stress? Musician, pet owner, and animal lover Janet Marlow may have sound solutions. With a background in classical music and a profound interest in the auditory world of animals, Marlow has dedicated her career to understanding how sound impacts emotional and physiological states in pets.

“I’ve always been deeply connected to music. It’s in my DNA as a fifth-generation musician. But it wasn’t until 1994, after moving from New York City to Connecticut, that I discovered how music could impact animals.” Marlow said, “I decided to live in Litchfield County because of the extraordinary beauty of nature that inspired so many compositions.” It was when Marlow adopted a black-and-white cat named Osborn that something remarkable happened. “Every time I played the guitar, Osborn would come to my side and relax. It was clear that the music was affecting him, and this sparked my curiosity,” she said. This sparked Marlow to start investigating how animals perceive sound and whether music could be used to improve their well-being.

Keep ReadingShow less